Exit·Healthcare/Life Sciences·June 10, 2026
GSK to acquire Deerfield-backed Nuvalent
The platform investment centers on a precision oncology company backed by Deerfield Management, in a transaction valued at up to $10, with transaction terms undisclosed in the announcement.
Takeaways
- Nuvalent, a clinical-stage precision oncology company founded and backed by Deer
- Deerfield’s Healthcare Innovation Fund profits will be donated to the Deerfield
BuyerGSK
TargetNuvalent
SponsorDeerfield Management
SellerDeerfield Management
TypeExit
IndustryHealthcare
Sub-sectorLife Sciences
GSK agreed to acquire Nuvalent, a precision oncology company backed by Deerfield Management, in a transaction valued at up to $10.6 billion.
The deal gives Deerfield an exit and adds Nuvalent's targeted cancer therapy pipeline to GSK.
Daily PE deal brief
Get Buyout Desk email updates.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up on the site. Email updates are not on a fixed schedule.